-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1444 Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction ChemotherapyClinically Relevant Abstract

Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, adult, Non-Biological therapies, Clinical Research, Combination therapy, drug development, Diseases, Therapies, Myeloid Malignancies, Study Population, Human
Saturday, December 10, 2022, 5:30 PM-7:30 PM

Suman Kambhampati, MD1*, Christine M. McMahon, MD2, Alireza Eghtedar, MD3*, Daniel A. Pollyea, MD4, Stephane de Botton, MD, PhD5*, Arnaud Pigneux6*, Mohamad Cherry, MD, MS7, Brian J Ball, MD8, Gautam Borthakur, MD9, Thomas Cluzeau, MD, PhD10*, Gary J. Schiller, MD11, Beibei Hu, MS12*, Angela Volkert12*, Joanie Aasen Gausman, MS, RN12*, Graeme Hodgson, PhD12*, David A. Roth, MD12, Erica D. Warlick, MD12, Michael J. Kelly, MD12* and Eytan Stein, MD13

1Sarah Cannon Cancer Institute, HCA Midwest Health, Research Medical Ctr, Kansas City, MO
2Anschutz Medical Campus, Division of Hematology, University of Colorado School of Medicine, Aurora, CO
3Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center, Denver, CO
4Anschutz Medical Campus, Division of Hematology, University of Colorado School of Medicine, Denver, CO
5Département d’hématologie et Département d’innovation thérapeutique, Gustave Roussy, Villejuif, France
6Hôpital Haut Lévêque, CHU de Bordeaux, Bordeaux, France
7Atlantic Health System, Carol Simon Cancer Center, Morristown, NJ
8City of Hope National Medical Center, Duarte, CA
9Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
10Clinical Hematology Department, Centre Hospitalier Universitaire de Nice, Nice, France
11David Geffen School of Medicine at UCLA, Los Angeles, CA
12Syros Pharmaceuticals, Inc., Cambridge, MA
13Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

RARA-positive AML is a novel genomically-defined subset with an actionable target for treatment with tamibarotene, an oral and selective RARα agonist (McKeown, Cancer Discovery 2017). Approximately 30% of non-APL AML patients are RARA-positive based on overexpression of the RARA gene in peripheral blood blasts as determined by an RT-PCR based assay (de Botton, ESH 2019). In patients with newly diagnosed (ND) AML ineligible for standard induction chemotherapy, tamibarotene/azacitidine led to a CR/CRi rate of 61% in RARA-positive patients with a rapid onset of response. The combination was well-tolerated with no increase in myelosuppression compared to azacitidine (aza) alone (de Botton, ASH 2020). Responses were observed irrespective of mutations or cytogenetic risk.

Approximately one-third of ND AML patients ineligible for standard induction therapy do not respond to venetoclax (ven) and nearly all eventually relapse (DiNardo, NEJM 2020). Translational data suggest that RARA-positive patients are enriched for monocytic features based on a positive Monocytic Expression Score (MES) that may be associated with ven resistance (Fiore, ASH 2020), suggesting that the blood-based RARA biomarker test selects for patients who may respond to tamibarotene and who may also be less likely to respond to ven/aza alone.

SELECT-AML-1 (NCT04905407) is a Phase 2, open-label, multi-center study in the US and France comparing the activity of tamibarotene/ven/aza to ven/aza in treatment-naive RARA‑positive ND AML patients ineligible for standard induction therapy.

The 3-part study includes a safety lead-in of the tamibarotene/ven/aza combination, a randomized efficacy study versus ven/aza, and a salvage arm for ven/aza only patients with primary endpoints of safety, CR/CRi rate, and overall response rate, respectively. Following the safety lead-in, patients will be randomized 1:1 to receive tamibarotene/ven/aza or ven/aza. In the salvage arm, patients randomized to ven/aza only who experience progressive disease, treatment failure, or relapse, will have tamibarotene added to their ven/aza regimen.

Patients currently enrolled in the safety lead-in are treated with starting doses of aza at 75 mg/m2 IV/SC daily on Days 1-7, ven on Days 1-28 per the ven USPI/SMPC, followed by tamibarotene at 6 mg twice per day PO on Days 8-28 of each 28-day cycle. Enrollment is ongoing.

As of 22 June 2022, six patients have enrolled to date, including four who are response-evaluable. Baseline characteristics of the response-evaluable patients include 75% male; median age 57 (55-74); median bone marrow blasts 55% (39-100%); cytogenetically normal (n=2), inversion 16 (n=1), del 5q and -7 (n=1); and molecular genetic testing normal (n=3), mutations of IDH2, BCOR, SRSF2, CSF3R, RUNX1 (n=1). The MES was high in 3 of 4 (75%) response evaluable patients consistent with a prior report in RARA-positive AML (Fiore, ASH 2020). All 4 response-evaluable patients achieved a best response of CR/CRi (2 CR, 2 CRi). The onset of response was rapid with all patients achieving an initial response after Cycle 1 (2 CR, 1 CRi, 1 MLFS). Median duration of treatment was 68 days (21-110). Two patients discontinued, both in remission, one due to death from neutropenic sepsis and the other by physician decision.

The adverse event (AE) profile of the triplet was consistent with reports of ven/aza in AML. AEs experienced by 2 or more patients (all grades/causality) included febrile neutropenia, pneumonia, anxiety, cough, diarrhea, fatigue, decreased appetite, myalgia, decreased neutrophil count, and decreased platelet count. The only serious AE (all causality) occurring in more than one patient was febrile neutropenia.

A high response rate was observed in early results of tamibarotene/ven/aza in RARA-positive ND AML patients ineligible for standard induction chemotherapy with 100% (4 of 4) response evaluable patients achieving CR/CRi, 3 of whom may have features of ven-resistance based on high MES. The triplet demonstrated an initial safety profile similar to ven/aza. Data from the safety lead-in will inform triplet dosing for the randomized portion of the study.

Disclosures: McMahon: Arcellx: Consultancy; Syros: Research Funding. Pigneux: Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees. Cherry: BMS: Other: Ad Board. Ball: Oncovalent: Membership on an entity's Board of Directors or advisory committees. Borthakur: Catamaran Bio, Abbvie, PPD Development, Protagonist Therapeutics, Janssen: Consultancy; Astex Pharmaceuticals, Ryvu, PTC Therapeutics: Research Funding; Pacylex, Novartis, Cytomx, Bio Ascend: Membership on an entity's Board of Directors or advisory committees. Cluzeau: Agios: Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: international congress, Speakers Bureau; Jazz Pharma: Speakers Bureau; Abbvie: Consultancy, Speakers Bureau; Celgen/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Speakers Bureau; Astellas: Speakers Bureau; Syros: Speakers Bureau; Pfizer: Other: international congress. Schiller: Pfizer: Research Funding; Gilead: Research Funding; Johnson & Johnson: Current equity holder in publicly-traded company; PreCOG LLC: Research Funding; Sangamo: Research Funding; Janssen: Research Funding; Cyclacel: Research Funding; Daiichi-Sankyo: Research Funding; Tolero: Research Funding; Medimmune: Research Funding; Millennium: Research Funding; Stemline: Speakers Bureau; Takeda: Research Funding; Cellerant: Research Funding; Actuate: Research Funding; Kite, a Gilead Company: Research Funding, Speakers Bureau; Incyte: Other: speaker fees, Research Funding, Speakers Bureau; Mateon: Research Funding; Trovagen: Research Funding; AstraZeneca: Honoraria; Constellation: Research Funding; Deciphera: Research Funding; Novartis: Honoraria, Other: Speaker fees, Research Funding; Bristol Myers Squibb: Current equity holder in publicly-traded company, Speakers Bureau; Cellectis: Research Funding; Forma: Research Funding; CTI: Research Funding; AVM Biopharma: Research Funding; Glycomimetics: Research Funding; Sellas: Research Funding; Stemline: Research Funding; FujiFilm: Research Funding; Deltafly: Research Funding; Gamida: Research Funding; Celgene: Consultancy, Research Funding, Speakers Bureau; Karyopharm: Research Funding, Speakers Bureau; Jazz: Consultancy; Samus: Research Funding; Regimmune: Research Funding; AltruBio: Research Funding; Amgen: Current equity holder in publicly-traded company, Honoraria; Arog: Research Funding; Onconova: Research Funding; Genentech-Roche: Research Funding; Geron: Research Funding; Ono Pharma: Honoraria; Astellas: Research Funding, Speakers Bureau; Agios: Consultancy, Honoraria; Actinium: Research Funding; AbbVie: Research Funding, Speakers Bureau. Volkert: Syros Pharmaceuticals, Inc.: Current Employment. Aasen Gausman: Syros Pharmaceuticals: Current Employment. Hodgson: Syros Pharmaceutical: Current Employment, Current equity holder in publicly-traded company. Roth: Syros Pharmaceuticals, Inc.: Current Employment, Current equity holder in publicly-traded company; Allarity Therapeutics, Inc.: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees. Warlick: Syros Pharmaceuticals: Current Employment. Kelly: Syros Pharmaceuticals, Inc.: Current Employment. Stein: PinotBio, Bristol Myers Squibb, Jazz Pharmaceuticals, Foghorn Therapeutics, Blueprint Medicines, Gilead Sciences, Janssen Pharmaceuticals: Consultancy; Auron Therapeutics: Current equity holder in private company; Daiichi-Sankyo, Celgene Pharmaceuticals, and Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas Pharmaceutical, Agios Pharmaceuticals, and Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; PTC Therapeutics and Syros: Membership on an entity's Board of Directors or advisory committees; Syndax: Consultancy, Research Funding; Bayer: Research Funding; Amgen, AbbVie, Seattle Genetics, and Biotheryx: Consultancy.

*signifies non-member of ASH